SiBone (NASDAQ:SIBN) SVP Sells $56,926.61 in Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,133 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $18.17, for a total transaction of $56,926.61. Following the sale, the senior vice president directly owned 270,517 shares of the company’s stock, valued at $4,915,293.89. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Performance

Shares of SIBN opened at $18.86 on Friday. The company has a 50-day moving average of $18.80 and a two-hundred day moving average of $16.28. The stock has a market cap of $836.42 million, a price-to-earnings ratio of -55.47 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. SiBone has a one year low of $11.48 and a one year high of $21.89.

SiBone (NASDAQ:SIBN) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. On average, equities research analysts expect that SiBone will post -0.4 earnings per share for the current year.

Analyst Ratings Changes

SIBN has been the subject of a number of research analyst reports. Truist Financial restated a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of SiBone in a report on Tuesday, August 4th. TD Cowen upped their price target on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. UBS Group increased their price objective on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.17.

Institutional Investors Weigh In On SiBone

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc raised its position in SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares in the last quarter. D.A. Davidson & CO. grew its position in SiBone by 5.7% in the first quarter. D.A. Davidson & CO. now owns 36,882 shares of the company’s stock worth $466,000 after acquiring an additional 1,991 shares in the last quarter. Diversified Trust Co increased its stake in shares of SiBone by 10.8% during the 1st quarter. Diversified Trust Co now owns 24,335 shares of the company’s stock worth $307,000 after purchasing an additional 2,375 shares during the last quarter. State of Wyoming increased its stake in shares of SiBone by 70.8% during the 1st quarter. State of Wyoming now owns 10,832 shares of the company’s stock worth $137,000 after purchasing an additional 4,490 shares during the last quarter. Finally, Quantinno Capital Management LP raised its holdings in shares of SiBone by 58.2% during the 1st quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock valued at $372,000 after purchasing an additional 10,848 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

SI-BONE, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company’s technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.

Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint.